SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The availability and affordability of orphan drugs for rare diseases in China
12 references·1 citing·36 second hop
The availability and affordability of orphan drugs for rare diseases in China (2016)The availability and affordability of orp…The Ecology of Medical Care in Beijing (2013)The Ecology of Medical Care i…Rare diseases and orphan drugs (2012)Rare diseases and orphan drugsPaying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? (2012)Paying for the Orphan Drug Sy…Orphan drugs: the regulatory environment (2012)Orphan drugs: the regulatory …Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU (2012)Orphan drugs, orphan diseases…Emerging issues in public health: A perspective on China’s healthcare system (2010)Emerging issues in public hea…Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years (2010)Emergence of orphan drugs in …Availability of and Access to Orphan Drugs (2010)Availability of and Access to…Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China (2009)Prices, availability and affo…Why rare diseases are an important medical and social issue (2008)Why rare diseases are an impo…Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Medicine prices, availability…Drugs for exceptionally rare diseases: do they deserve special status for funding? (2005)Drugs for exceptionally rare …Artificial intelligence empowering rare diseases: a bibliometric perspective over the last two decades (2024)Artificial intelligence empow…Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries (2003)Assessing the economic challenges posed by orphan drugs (2007)Economics of New Oncology Drug Development (2007)Patient Access to Medicines for Rare Diseases in European Countries (2018)Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases (2006)The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs (2015)Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (2017)Priority setting of health interventions: the need for multi-criteria decision analysis. (2006)Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Outrageous prices of orphan drugs: a call for collaboration (2018)A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries (2020)Rare diseases, orphan drugs and their regulation: questions and misconceptions (2010)Orphan drugs policies: a suitable case for treatment (2014)Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen (2017)The Future Role of the United States in Global Health (2017)Setting Health Care Priorities in Oregon (1991)Intergenerational Equity: An Exploration of the ‘Fair Innings’ Argument (1997)QALY maximisation and people's preferences: a methodological review of the literature (2004)A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? (2017)Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group (2018)China statistical yearbook (1988)Social determinants of health inequalities (2005)Social determinants of health inequalities (2005)Determinants of basic public health services provision by village doctors in China: using non-communicable diseases management as an example (2015)Catastrophic health expenditure on acute coronary events in Asia: a prospective study (2016)Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (2014)Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework (2014)Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation (2015)The supportive care needs of parents with a child with a rare disease: results of an online survey (2016)Alone in a Crowd? Parents of Children with Rare Diseases’ Experiences of Navigating the Healthcare System (2018)Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives (2012)THE WORLD MEDICINES SITUATION 2011 (2011)The Economic Costs of Type 2 Diabetes: A Global Systematic Review (2015)Essential medicines for universal health coverage (2016)
this work references cited by second hop

References

  • 2008Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis926 cited
  • 2008Why rare diseases are an important medical and social issue621 cited
  • 2005Drugs for exceptionally rare diseases: do they deserve special status for funding?220 cited
  • 2012Rare diseases and orphan drugs214 cited
  • 2012Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?171 cited
  • 2010Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years148 cited
  • 2012Orphan drugs: the regulatory environment144 cited
  • 2012Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU111 cited
  • 2010Emerging issues in public health: A perspective on China’s healthcare system95 cited
  • 2010Availability of and Access to Orphan Drugs87 cited
  • 2009Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China87 cited
  • 2013The Ecology of Medical Care in Beijing44 cited

Cited by

  • 2024Artificial intelligence empowering rare diseases: a bibliometric perspective over the last two decades10 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work